Axcellant participated in SNMMI’s 2025 Annual Meeting in New Orleans, where nearly 8,000 professionals in nuclear medicine and molecular imaging gathered to discuss cutting-edge developments, and the Image of the Year was a novel peptide-based PET tracer targeting PD-L1 in head and neck cancers.
Sessions covered the latest in tracer development, theranostics, total-body PET, and AI-powered imaging strategies. The apparent excitement and rapid learning between established researchers and rising talent underscore how quickly the field is evolving.
These innovations are more than academic—they inform the development of better diagnostic tools and smarter clinical trial designs. Axcellant is excited to apply insights from SNMMI 2025 to strengthen our imaging‑focused clinical research services, helping advance patient care through precision and innovation.
3 Questions with: Prof. Piotr Słomka Large language models are entering nuclear cardiology at a pace that makes the usual…
How Axcellant helped a diagnostic study overcome isotope supply, manufacturing, and logistics constraints In radiopharmaceutical development, we often say that…
Europe’s clinical trials market is entering a more practical phase in its approach to competitiveness. With the Clinical Trials Regulation…
Copyright @ 2026 Axcellant